Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in Chronic Myeloid Leukemia patients of Kashmir

Meta Gene ◽  
2018 ◽  
Vol 17 ◽  
pp. 93-98 ◽  
Author(s):  
Niyaz A. Azad ◽  
Zafar A. Shah ◽  
Arshad A. Pandith ◽  
Roohi Rasool ◽  
Javed A. Rasool ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Imatinib Resistance ◽  
Abl Kinase ◽  
Kinase Domain Mutations

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

Blood ◽  
2007 ◽  
Vol 110 (7) ◽  
pp. 2242-2249 ◽  
Author(s):  
Thomas O'Hare ◽  
Christopher A. Eide ◽  
Michael W. N. Deininger
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Therapeutic Potential ◽  
Kinase Domain ◽  
Imatinib Resistance ◽  
The Road ◽  
Abl Kinase ◽  
Imatinib Resistant ◽  
Kinase Domain Mutations

Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations before and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor–resistant 315T>I mutant and the therapeutic potential that a 315T>I inhibitor would have. Last, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis.

Detection of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia Patients

2016 ◽  
Vol 16 ◽  
pp. S60
Author(s):  
Nancy Escobar ◽  
Mariana Herrera ◽  
Luisa Rosales ◽  
Silvana Torselli ◽  
Julio Caceres ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Kinase Domain Mutations

scholarly journals PB1920 BCR-ABL GENE ABL KINASE DOMAIN MUTATIONS IN IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS FROM AZERBAIJAN

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 873-874
Author(s):  
C. Asadov ◽  
A. Hasanova ◽  
A. Shirinova ◽  
N. Karimova ◽  
Z. Alimirzoeva
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Imatinib Resistant ◽  
Kinase Domain Mutations

Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India

Tumor Biology ◽  
2014 ◽  
Vol 35 (7) ◽  
pp. 7187-7193 ◽  
Author(s):  
Sailaja Kagita ◽  
Srihari Uppalapati ◽  
Sangeeta Jiwatani ◽  
Vijay Gandhi Linga ◽  
Sadasivudu Gundeti ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
South India ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Kinase Domain Mutations

Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq

2020 ◽  
Vol 23 (06) ◽  
pp. 01-07
Author(s):  
Muhammed Sadiq Mahdi Al- Musawi ◽  
Sameer Hasan Abbood ◽  
Liwaa Hussein Mahdi ◽  
Rahem Mahdy Rahem
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Kinase Domain Mutations

Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib

Hematology ◽  
2013 ◽  
Vol 18 (6) ◽  
pp. 328-333 ◽  
Author(s):  
Bahram Chahardouli ◽  
Farhad Zaker ◽  
Seied Asadollah Mousavi ◽  
Zeinab Saffari ◽  
Fatemeh Nadali ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Kinase Domain Mutations
Sign in / Sign up

Export Citation Format

Share Document